VEGFA and retinal disorder: The absence of routine pharmacovigilance and the general risks of compounding and off-label use of medications not intended for ocular use all add to the still partially unknown safety profile of bevacizumab for the treatment of retinal disorders, when compared with licensed anti-VEGF agents [23].